546 817

Cited 19 times in

Treatment Outcome and Prognostic Molecular Markers of Supratentorial Primitive Neuroectodermal Tumors.

 Seo Hee Choi  ;  Se Hoon Kim  ;  Kyu-Won Shim  ;  Jung Woo Han  ;  Junjeong Choi  ;  DongSeok Kim  ;  Chuhl Joo Lyu  ;  Jun Won Kim  ;  Chang-Ok Suh  ;  Jaeho Cho 
 PLOS ONE, Vol.11(4) : e0153443, 2016 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Basic Helix-Loop-Helix Transcription Factors/metabolism ; Biomarkers, Tumor/metabolism* ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Humans ; Infant ; Male ; Middle Aged ; Nerve Tissue Proteins/metabolism ; Neuroectodermal Tumors, Primitive/metabolism ; Neuroectodermal Tumors, Primitive/pathology ; Neuroectodermal Tumors, Primitive/therapy* ; Oligodendrocyte Transcription Factor 2 ; Prognosis ; RNA-Binding Proteins/metabolism ; Rad51 Recombinase/metabolism ; Supratentorial Neoplasms/metabolism ; Supratentorial Neoplasms/pathology ; Supratentorial Neoplasms/therapy* ; Treatment Outcome ; Young Adult
BACKGROUND: To identify prognostic factors and define the optimal management of patients with supratentorial primitive neuroectodermal tumors (sPNETs), we investigated treatment outcomes and explored the prognostic value of specific molecular markers.
METHODS: A total of 47 consecutive patients with pathologically confirmed sPNETs between May 1985 and June 2012 were included. Immunohistochemical analysis of LIN28, OLIG2, and Rad51 expression was performed and correlated with clinical outcome.
RESULTS: With a median follow-up of 70 months, 5-year overall survival (OS) and progression-free survival (PFS) was 55.5% and 40%, respectively, for all patients. Age, surgical extent, and radiotherapy were significant prognostic factors for OS and PFS. Patients who received initially planned multimodal treatment without interruption (i.e., radiotherapy and surgery (≥subtotal resection), with or without chemotherapy) showed significantly higher 5-year OS (71.2%) and PFS (63.1%). In 29 patients with available tumor specimens, tumors with high expression of either LIN28 or OLIG2 or elevated level of Rad51 were significantly associated with poorer prognosis.
CONCLUSIONS: We found that multimodal treatment improved outcomes for sPNET patients, especially when radiotherapy and ≥subtotal resection were part of the treatment regimen. Furthermore, we confirmed the prognostic significance of LIN28 and OLIG2 and revealed the potential role of Rad51 in sPNETs.
Files in This Item:
T201601267.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pediatrics (소아과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers
Yonsei Authors
Kim, Dong Seok(김동석)
Kim, Se Hoon(김세훈) ORCID logo https://orcid.org/0000-0001-7516-7372
Kim, Jun Won(김준원) ORCID logo https://orcid.org/0000-0003-1358-364X
Suh, Chang Ok(서창옥)
Shim, Kyu Won(심규원) ORCID logo https://orcid.org/0000-0002-9441-7354
Lyu, Chuhl Joo(유철주) ORCID logo https://orcid.org/0000-0001-7124-7818
Cho, Jae Ho(조재호) ORCID logo https://orcid.org/0000-0001-9966-5157
Choi, Seo Hee(최서희) ORCID logo https://orcid.org/0000-0002-4083-6414
Han, Jung Woo(한정우) ORCID logo https://orcid.org/0000-0001-8936-1205
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.